All News

If you do not practice self-care, you won't be able to care for the one you love.

A Lartruvo (olaratumab) combination received an accelerated approval from the FDA to treat patients with soft tissue sarcoma.

A new tool that grades financial toxicity similar to adverse events may help patients deal with finances during cancer.

A two-time cancer survivor shares her experiences with cancer's side effects.

Tecentriq was approved by the U.S. Food and Drug Administration (FDA) for some patients with lung cancer.

The Beat AML trial just launched, and researchers are hoping it will find better treatment for patients with acute myeloid leukemia.

A trial testing Zytiga's effectiveness in ovarian cancer was recently halted.

Healing from breast cancer is difficult, but sometimes the changes are worthwhile.

LaTour clearly remembers the day of her diagnosis three decades ago.

The three winners of an international competition were awarded grant money to further develop their innovations to better the lives of patients with cancer.

A computer simulation tool may help plan treatment for certain patients with recurrent glioblastoma.

Recovery is an up-and-down process, and it's okay to show yourself compassion through the ups and the downs.

Know when that pink ribbon makes a difference (and when it doesn't).

As the treatment paradigm shifts for triple-negative breast cancer, PARP inhibitors will continue to play a role.

Subsets of patients with acute lymphoblastic leukemia are getting more personalized care.

After doing well in a phase 3 trial, Stivarga showed the potential to shift the treatment paradigm for previously treated liver cancer.

Scanxiety due to a scheduled or surprise scan or ultrasound can trigger those thoughts and fears of cancer recurrence at any moment.

Women breast cancer survivors explain what they want to hear from the men in their lives.

Yervoy reduced risk of death for patients with high-risk stage 3 melanoma in a recent study.

The addition of immunotherapy did not show an improved progression-free survival for some patients with head and neck cancer.

A new drug combination showed improved progression-free survival for patients with advanced melanoma, according to a recent study.

Patients with DNA mismatch repair deficiency rectal cancer may not necessarily have Lynch syndrome. Expert Yi-Qian Nancy You weighs in on the topic.

Cancer survivor rethinks her home for easier management after cancer.

Choosing active surveillance did not increase stress levels for men with low-risk prostate cancer, according to a recent study.

Michael Choti talks about what kind of advances can be expected in treating liver cancer, including PD-1 inhibitors and neoadjuvant treatment.

A recent trial presented an unexpected survival benefit for patients with high-risk soft tissue sarcoma who were on anthracycline-based neoadjuvant chemotherapy.

Johnson writes about seeing clearly when the storm clouds settle.